Matthew J. Reilley, MD | Oncology | UVA

Dr. Matthew J. Reilley

Claim this profile

University of Virginia Cancer Center

Studies Cancer
Studies Pancreatic Cancer
16 reported clinical trials
43 drugs studied

Area of expertise

1

Cancer

Matthew J. Reilley has run 7 trials for Cancer. Some of their research focus areas include:

Stage IV
KRAS positive
BRAF positive
2

Pancreatic Cancer

Matthew J. Reilley has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
KRAS positive
BRAF positive

Affiliated Hospitals

Image of trial facility.

University Of Virginia Cancer Center

Image of trial facility.

University Of Virginia

Clinical Trials Matthew J. Reilley is currently running

Image of trial facility.

NDI-219216

for Cancer

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.

Recruiting

1 award

Phase 1 & 2

2 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Bile Duct Cancer

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab with gemcitabine and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed in patients with high risk resectable cholangiocarcinoma.

Recruiting

1 award

Phase 2

More about Matthew J. Reilley

Clinical Trial Related

1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Matthew J. Reilley has experience with

  • Oxaliplatin
  • Fluorouracil
  • Binimetinib
  • Palbociclib
  • Pembrolizumab
  • Leucovorin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Matthew J. Reilley specialize in?

Is Matthew J. Reilley currently recruiting for clinical trials?

Are there any treatments that Matthew J. Reilley has studied deeply?

What is the best way to schedule an appointment with Matthew J. Reilley?

What is the office address of Matthew J. Reilley?

Is there any support for travel costs?